Argus downgrades Moderna to hold on weak near-term outlook

Argus downgraded Moderna to "hold" due to declining COVID-19 vaccine sales, limited growth, and challenges for its RSV vaccine despite a promising development pipeline.

MicroStrategy stock surges on Nasdaq-100 inclusion announcement

MicroStrategy shares rose 6% as it joins Nasdaq-100, boosting its Bitcoin-focused strategy and market cap to nearly $94 billion, with potential for S&P 500 inclusion.

U.S. stocks lower at close of trade; Dow Jones Industrial Average down 0.35%

U.S. stocks fell Tuesday, driven by losses in major sectors. Dow, S&P 500, and NASDAQ indexes declined, with notable shifts in individual stock performances.

BofA reinstates pharma coverage

Bank of America reviews 11 U.S. pharma stocks, highlighting growth potential and challenges amid patent cliffs and pricing pressures while recommending buy, neutral, and underperform ratings.

Novavax to sell Czech manufacturing unit to Novo Nordisk for $200 million

Novavax sells its Czech manufacturing facility to Novo Nordisk for $200 million to boost its vaccine pipeline and reduce costs, amid struggles with COVID-19 vaccine competition.

Moderna shares could slump over 30% on negative CMV reading: Leerink

Moderna's stock could drop over 30% on negative CMV vaccine trial results, but a positive readout could see shares rise to mid-$50s, impacting long-term revenue prospects.

U.S. stocks higher at close of trade; Dow Jones Industrial Average up 0.97%

Jefferies says market nears short term “peak RFK negativity", Vaccine makers up

U.S. stocks mixed at close of trade; Dow Jones Industrial Average down 0.28%

U.S. stocks showed mixed results with gains in some sectors and losses in others, impacting major indices differently.

Moderna stock climbs as HSBC upgrades to Buy on underestimated pipeline potential

Moderna shares rose after HSBC upgraded the stock, predicting potential growth through new products and market opportunities, while addressing profitability delays and market skepticism.